Our findings may provide important novel evidence on immune-related etiologic pathways that interact with lifestyle factors, influencing breast cancer risk, and suggest the potential clinical use of CRP to predict specific cancer subtypes and CRP–inflammatory marker-targeting interventions to reduce breast cancer risk in postmenopausal women. The gene discussed is CRP; the disease is breast carcinoma.